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Abstract
Background: Individuals infected with human immunodeficiency virus (HIV) have an increased risk of progression
to active tuberculosis following Mycobacterium tuberculosis infection. The objective of the study was to determine
IFN-g responses for the detection of latent tuberculosis infection (LTBI) with QuantiFERON-TB GOLD In Tube (QFT-G-
IT) and T-SPOT.TB in HIV patients, and evaluate the influence of CD4 cell count on tests performance.
Methods: We studied 75 HIV patients enrolled for ongoing studies of LTBI with T-SPOT.TB, QFN-G-IT and TST.
Mean CD4 cell counts ± standard deviation was 461.29 ± 307.49 cells/μl. Eight patients had a BCG scar.
Results: T-SPOT.TB, QFN-G-IT and TST were positive in 7 (9.3%), 5 (6.7%) and 9 (12%) cases, respectively. Global
agreement between QFN-G-IT and T-SPOT.TB was 89% ( = 0.275). The overall agreement of T-SPOT.TB and QFN-
G-IT with TST was 80.8% ( = 0.019) and 89% ( = 0.373), respectively. We have found negative IFN-g assays results
among 2 BCG-vaccinated HIV-infected individuals with a positive TST. In non BCG-vaccinated patients, QFN-G-IT
and TST were positive in 5 cases (7.5%) and T-SPOT.TB in 7 (10.4%). In contrast, in BCG-vaccinated patients, only
TST was positive in 4/8 (50%) of the cases. The differences obtained in the number of positive results between TST
and both IFN-g assays in BCG vaccinated patients were significant (95% CI 3-97%, p = 0.046), however, the
confidence interval is very wide given the small number of patients. In patients with CD4< 200, we obtained only
one (5%) positive result with T-SPOT.TB; however, QFN-G-IT and TST were negative in all cases. On the contrary,
percentages of positive results in patients with CD4> 200 were 10.9% (6/55), 9.1% (5/55) and 16.4% (9/55) with T-
SPOT.TB, QFN-G-IT and TST, respectively.
Conclusions: IFN-g tests have the benefit over TST that are less influenced by BCG vaccination, consequently they
are more specific than TST. Although our number of patients with advance immunosuppression is limited, our
study suggests that IFN-g assays are influenced with level of immunosuppression. The use of IFN-g assays could be
a helpful method for diagnosing LTBI in HIV population.
Background
Tuberculosis (TB) is still a major cause of morbidity and
mortality throughout the world. There is an estimated
global incidence of 8.8 million new cases, with a total of
1.6 million deaths [1]. Indeed, individuals infected with
human immunodeficiency virus (HIV) have an increased
risk of progression to active TB following Mycobacterium
tuberculosis infection of 5-10% per year [2]. The detec-
tion and treatment of active TB is crucial to control the
global TB epidemic. Therefore, targeting and treating
infected persons with high risk of disease reactivation is a
key strategy for an effective control of the spread of TB.
Nevertheless, the diagnosis of latent tuberculosis infec-
tion (LTBI) is complicated due to the lack of a gold
standard test. Tuberculin skin test (TST) has been used
since the last century for diagnosing LTBI. TST mea-
sures a cell-mediated immunity as the form of a
delayed-type hypersensitivi t yr e s p o n s et ot h ep u r i f i e d
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TST is its lack of specificity. PPD contains more than 200
antigens that are shared among other mycobacteria such
as the Bacille Calmette-Guérin (BCG) vaccine strain and
many non-tuberculous mycobacteria (NTM), conse-
quently, false positive TST results can occur due to anti-
genic cross-reactivity [4]. In addition, the sensitivity of
TST is reduced in HIV-positive patients because of false
negative results, as a result of cutaneous anergy [5].
New in vitro T-cell based assays for the diagnosis of
LTBI are now available. These assays measure the IFN-
gamma (IFN-g) released by sensitized T cells after speci-
fic M. tuberculosis antigen stimulation. These specific
antigens are early secreted antigenic target 6 (ESAT-6)
and culture filtrate protein 10 (CFP-10), which are
encoded in the region of difference 1 (RD1) segment of
M. tuberculosis genome [6], and TB7.7, encoded in
RD11 segment [7].
Nowadays, there are two commercial available IFN-g
T-cell based assays: QuantiFERON-TB GOLD In Tube
(QFN-G-IT, Cellestis Limited, Carnegie, Australia) and
T-SPOT.TB (Oxford Immunotec Limited, Abingdon,
UK). Both assays are approved from the U.S. Food and
Drug Administration (FDA) as an aid for diagnosing
LTBI. QFN-G-IT test stimulates whole-blood with
ESAT-6, CFP-10 and TB7.7 in the same tube, and mea-
sures the concentration of IFN-g in supernatants with
an enzyme-linked-immunosorbent assay (ELISA). On
the other hand, T-SPOT.TB assay stimulates isolated
peripheral blood mononuclear cells (PBMCs) with
ESAT-6 and CFP-10 separately, and detects number of
IFN-g producing T cells by means of an enzyme-linked
immunospot assay (ELISPOT).
Promising results have been published with IFN-g assays
in the diagnosis of LTBI [8-13] and active TB [14-18].
Moreover, in the last years some studies have studied IFN-
g tests in HIV-infected population [19-23]. However, only
few studies comparing the performance of both T-SPOT.
TB and QFN assays in the same HIV population have
been conducted [19,24-27]. However, more studies com-
paring T-SPOT.TB and QFN-G-IT with TST are required
in order to better understand the role of IFN-g assays in
the diagnosis of LTBI in this kind of population, analyzing
the impact of the degree of immunosuppression on the
antigen-specific T-cell responses.
So, in the present study, we compared the utility of T-
SPOT.TB, QFN-G-IT and TST for the diagnosis of LTBI
in the same HIV population, and evaluated the influence
of CD4 cell count on the different tests performance.
Methods
Study setting and patient recruitment
From January 2006 through November 2009, HIV-posi-
tive adults attending to the Hospital Universitari
Germans Trias i Pujol and Hospital Universitari Mútua
Terrassa were enrolled for ongoing studies of LTBI. The
estimated TB community incidence of TB is 23.2/
100.000 habitants and the HIV prevalence among those
active TB patients is 8.5% [28].
Patients were consecutively recruited, and were
enrolled during the course of the routine examinations.
Each participant gave written informed consent before
blood sampling. Ethics Committees of Hospital Univer-
sitari Germans Trias i Pujol and Hospital Universitari
Mútua Terrassa approved the study. Information on the
following variables was collected completing a detailed
questionnaire: age, gender, BCG vaccination, prior TST
(date and result), TB contact, history of prior active TB,
chest radiography and other medical conditions. In our
study, only participants with BCG scars were considered
BCG vaccinated. In LTBI patients, active TB was
excluded by clinical and radiologic examination. None
of the patients included in this study had active TB.
Patients were tested during the routine examination
with the TST. Blood sampling of IFN-g assays was per-
formed before TST application. Patients with a previous
documented positive TST were excluded.
HIV testing and lymphocyte count
HIV testing was performed in all subjects. Blood sam-
ples were taken for HIV serology (ELISA and Western-
Blot). CD4 and CD8 cell count were performed on
blood samples from all HIV-positive patients.
Tuberculin skin test
Two intradermal tuberculin units of PPD RT23 Tween
80 (Statens Serum Institut, Copenhagen, Denmark) were
used to perform the TST, using the Mantoux method.
Induration was measured 48-72 h after the application,
and the size of the induration was interpreted by trained
personnel. According to our national guidelines, an
induration equal or highert h a n5m mw a sc o n s i d e r e d
positive [29].
QuantiFERON-TB GOLD In Tube
A total of three tubes of one millilitre each: nil control,
positive control (phytohaemagglutinin [PHA]) and TB-
specific antigens were drawn by venopuncture from
each patient. The tubes were incubated overnight at 37°
C, and after incubation plasmas were separated by cen-
trifugation. The production of IFN-g in whole-blood
supernatant was determined by an ELISA.
Raw optical densities were interpreted by using speci-
f i cs o f t w a r ep r o v i d e db yt h em a n u f a c t u r e r .T h er e s u l t
obtained by the nil control was subtracted from the
positive control and the antigen-stimulated samples.
The cut-off value for a positive test was at least 0.35 IU/
mL of IFN-g in the sample after stimulation with the
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control. The result of the test was considered indetermi-
nate if the antigen-stimulated sample was negative and
if the value of the positive control was less than 0.5 IU/
mL after subtraction of the value of the nil control; and/
or if the negative control was higher than 8.0 IU/mL.
T-SPOT.TB
Eight millilitres of blood were drawn for the isolation of
PBMCs in a vaccutainer CPT tube (Beckton Dickinson
Diagnostics, Franklin Lakes, NJ). The isolated PBMCs
were washed twice by centrifugation with RPMI med-
ium (Invitrogen, Auckland, N.Z.), and later resuspended
in AIM-V medium (Invitrogen, Auckland, N.Z.). Finally,
viable cells were counted with an inverted microscope
using the tripan blue method.
IFN-g producing T cells were detected by an enzyme-
linked immunospot assay (ELISPOT). The test was per-
formed according the manufacturer’s instructions. Each
subject requires four wells precoated with a monoclonal
antibody to IFN-g. In the first well, cells were incubated
with medium alone (control negative), in the second
one with PHA (control positive), in the third one with
ESAT-6 (Panel A), and in the last one with CFP-10
(Panel B). The assay requires a total of 250,000 cells per
well.
On T-SPOT.TB, spots were scored using an auto-
mated AID ELISPOT plate reader (Lector AID Elispots,
Autoimmun Diagnostiks GMBH, Germany). All readings
were also manually verified. Each spot represents the
footprint of a cytokine secreting cell and the number of
spots obtained provides a measurement of frequency of
M. tuberculosis sensitized cells. Subjects were considered
positive if there was a positive response to one or both
of the antigen panels. Test wells were scored as positive
if they contained at least six spot-forming cells more
than the nil control well and this number was at least
twice the number of the nil control well. The result was
considered indeterminate if the response to both antigen
panels were negative and if the number of spots in the
control positive well was less than 20. In addition, the
immunoresponse was also considered indeterminate if
the number of spots in the negative control was greater
than 10.
Statistical methods
Concordance between both tests was assessed using
Cohen’s Kappa () coefficient.  values below 0.40 indi-
cate weak correlation, values of 0.41-0.60 indicate good
agreement and values above 0.60 indicate strong agree-
ment. Comparison of the number of spots and the
IFN-g released was performed by Mann-Whitney U test
analysis. Differences were considered significant when
P values were less than 0.05. All analyses were made
with SPSS statistical software for Windows (SPSS ver-
sion 15.0; SPSS Inc., Chicago; IL, USA). Graphical repre-
sentation is based on GraphPad Prism version 4
(GraphPad Software, Inc, Dan Diego, CA).
Results
Patient characteristics
We studied 75 HIV-positive patients who were screened
for LTBI. Mean CD4 and CD8 cell counts ± standard
deviation were 461.29 ± 307.49 cells/μl and 899.33 ±
649.94 cells/μl respectively. The main demographic
characteristics of patients included in the study are sum-
marized in Table 1.
Diagnostic tests performance
The overall number of positive results in HIV-positive
individuals screened for LTBI was 7/75 (9.3%), 5/75
(6.7%) and 9/75 (12%) using T-SPOT.TB, QFN-G-IT
and TST respectively. There were not significant differ-
ences in the percentage of positive results between the
three tests. We obtained two indeterminate results, both
by T-SPOT.TB and QFN-G-IT, due to an insufficient
response to PHA and M. tuberculosis specific antigens.
In these two cases, TST was negative. Global agreement
between T-SPOT.TB and QFN-G-IT was 89% ( =
0.275; standard error [SE] = 0.184). The overall agree-
ment of T-SPOT.TB and QFN-G-IT with TST was
80.8% ( = 0.019; SE = 0.123) and 89% ( =0 . 3 7 3 ;S E=
0.173), respectively.
In non BCG-vaccinated patients, QFN-G-IT and TST
were positive in 5/67 (7.5%), and T-SPOT.TB in 7/67
(10.4%) of the cases. In BCG-vaccinated patients both
IFN-g assays were negative, but in contrast, we obtained
4/8 (50%) of positive results with TST. The difference
between the results obtained by TST in non BCG-vacci-
nated and BCG-vaccinated was statistically significant (p
= 0.006). Furthermore, the differences obtained in the
number of positive results between TST and both IFN-g
assays in BCG vaccinated patients were also significant
(95% Confidence interval = 3-97%, p = 0.046), however,
the confidence interval is very wide given the small
number of patients. The number of positive results
and the agreement between the assays regarding BCG-
vaccination status are shown in Tables 2 and 3.
Influence of CD4 cell count
We analyzed the possible impact of CD4 cell count on
T cell responses, stratifying patients into two groups: 20
patients with < 200 CD4 cells/μl and 55 patients with
>200 CD4 cells/μl. We found that number of responder
T cells to specific M. tuberculosis antigens detected by
T-SPOT.TB and the IFN-g released in QFN-G-IT was
lower in HIV-positive patients with CD4 cell counts
< 200 than >200 cells/μl but not statistically significant,
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T cell responses on QFN-G-IT according CD4 T cells
and the differences between < 200 and >200 cell counts
were nearly significant (Figure 2). On the other hand, it
was impossible to asses the number of responder T cells
after PHA stimulation on T-SPOT.TB due to saturation
in the control positive well.
The proportion of positive results obtained by
T-SPOT.TB and QFN-G-IT were lower in HIV patients
with a CD4 cell count < 200 than above >200 cells/μl.
In patients with a CD4 cell count below 200, we only
obtained an only one (5%) positive result with T-SPOT.
TB, that corresponded to one patient with 39 CD4 cells/
μl. QFN-G-IT and TST were negative in all cases. In
contrast, percentages of positive results in patients with
a CD4 cell count above 200 were 10.9% (6/55), 9.1% (5/
55) and 16.4% (9/55) with T-SPOT.TB, QFN-G-IT and
TST, respectively. Differences in positive results regard-
ing CD4 cell count were not significant for any tests (T-
SPOT.TB, QFN-G-IT and TST: p = 0.313, p = 0.123
and p = 0.055, respectively).
The concentration of IFN-g released in QFN-G-IT and
the number of responder ESAT-6 and CFP-10 specific
T cells detected by T-SPOT.TB was not correlated with
number of circulating CD4 T cells (Spearman’s rho [SR]
= 0.221, p = 0.056; SR = 0.028, p = 0.813 and SR =
0.013, p = 0.910, respectively), as shown in Figure 3.
Discussion
Several authors have studied the responses on T-cell
based assays in HIV individuals for the detection of
LTBI and active TB. It has been demonstrated in the
majority of the studies, that IFN-g assays have higher
number of positive results than TST and a poor agree-
ment with it [19-21,23,30-34]. Nevertheless, only a few
studies have performed a direct comparison of T-SPOT.
TB, QFN-G-IT and TST to ascertain LTBI in HIV-
positive individuals [24-27].
Talati et al [25], compared T-SPOT.TB, QFN-G-IT
and TST in 336 HIV-infected persons. They found a
low prevalence of LTBI with the three diagnostic tests: 7
(2.1%) had a positive TST, 9 (2.7%) a positive QFN-G-
IT and 14 (4.2%) a positive T-SPOT.TB. Overall, agree-
ment between the three diagnostic tests was poor.
Furthermore, Richeldi et al [24], performed simulta-
neously T-SPOT.TB, QFN-G-IT and TST in 116 chroni-
cally HIV-infected individuals. They identified a low
percentage of individuals as LTBI and also a slight
agreement between T-SPOT.TB and TST or QFN-G-IT.
Rivas I [27] compared TST and both IFN-g tests in 139
drug and alcohol abusers, 31% of them being HIV-
infected patients. The authors did not found statistically
significant associations between HIV serostatus and in
vitro tests or TST. However, percentages of positive
results obtained by T-SPOT.TB and QFN-G-IT in HIV-
positive patients were higher for patients with a CD4
count >350 cells/μl than < 350 cells/μl (28.6% and
39.3% versus 20% and 10%, respectively).
On the other hand, the evaluation of both T-cell based
assays and the TST, in patients with HIV-infection, for
the immunodiagnosis of LTBI has been also recently
described in a high TB-incidence country. In this sense,
Leidl et al [26] enrolled 109 individuals in Uganda with
a new diagnosis of HIV-1 infection, and observed that
global frequencies of positive results for TST, T-SPOT.
TB and QFN-G-IT were 47.2%, 54% and 67.9% respec-
tively. Although there are few differences between
Table 1 Demographic characteristics of patients included in this study
All subjects
N = 75 (%)
CD4< 200
N = 20 (%)
CD4 >200
N = 55 (%)
Gender
Male 53 (70.7) 15 (75) 38 (69.1)
Female 22 (29.3) 5 (25) 17 (30.9)
Age, mean ± SD 42.41 ± 9.16 42.10 ± 7.96 42.53 ± 9.63
BCG-vaccinated
Yes 8 (10.7) 2 (10) 6 (10.9)
No 67 (89.3) 18 (90) 49 (89.1)
Birth country
Immigrants from countries with high prevalence of TB infection 6 (8) 1 (5) 5 (9.1)
Autochthonous Spanish population 69 (92) 19 (95) 50 (90.9)
Table 2 T-SPOT.TB, QFN-G-IT and TST positive results
regarding BCG vaccination status
Diagnostic test No. (%) of positive results
BCG-vaccinated
(n = 8)
Non BCG-vaccinated
(n = 67)
p*
T-SPOT.TB 0 (0) 7 (10.4) 0.531
QFN-G-IT 0 (0) 5 (7.5) 0.683
TST 4 (50) 5 (7.5) 0.006
*Significance value in percentage of positive results between BCG and non-
BCG vaccinated patients.
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our results are consistent with those reported in the
referred studies, where the commercial IFN-g tests
reached similar number of positive results. Furthermore,
according to these studies we observed that concor-
dances between three diagnostic tests were poor.
Intriguingly, we have observed poor agreement
between both IFN-g tests. From the 7 cases with a posi-
tive T-SPOT.TB result and the 5 cases with positive
QFN-G-IT results, both tests were positive simulta-
neously in only 2 cases. Diagnostic agreement between
tests was moderate ( = 0.40-0.65). Similar results were
d e s c r i b e db yR i c h e l d ie ta l[ 2 4 ] .T h e yo b s e r v e dt h a tt h e
agreement decreased in the HIV group when T-SPOT.
TB was compared with either TST ( = 0.16) or QFT-
IT ( = 0.19). In addition they reported highly discor-
dant results (those clearly negative with one IFN-g assay
and clearly positive with another) in all groups of immu-
nosuppressed patients. The analysis of these discordant
results needs to be researched further.
It is poorly understood the impact of the HIV-infection
in the immune response of LTBI and vice versa. We have
observed, as other authors [24], the presence of discor-
dant results between the TST and the IFN-g tests, and
also between both IFN-g tests (T-SPOT.TB and QFN-
G-IT). It is not clear enough the reasons for these kinds
of results. In some cases it could be given by BCG
vaccination, or by previous NTM infections (discor-
dances between TST and IFN-g tests). In other cases, it
might be due to the different methodologies (TST vs
QFN-G-IT vs T-SPOT.TB). In fact, maybe, the discor-
dant results demonstrate some different immune
responses [35], but this hypothesis has not been yet fully
explored. In any case, given that a gold standard for LTBI
does not exist, it is not possible to know, in case of dis-
cordant result, which test gives the true result. So, do we
recommend doing TST and IFN-g tests to all HIV
patients? We think that we have to do more diagnostic
effort in patients with a high risk of developing active TB
if they are infected. Probably we have to use all the tests
available in severe immunosuppresed patients, and
maybe it is not so necessary in HIV patients with a con-
served number of CD4. Therefore, the use of IFN-g
Table 3 Concordance and agreement between TST, T-SPOT.TB and QFN-G-IT results according BCG vaccination status*
TST vs T-SPOT.TB TST vs QFN-G-IT T-SPOT.TB vs QFN-G-IT
Concordance (%)  (SE**) Concordance (%)  (SE) Concordance (%)  (SE)
HIV-positive
Overall 59/73 (80.8) 0.019 (0.123) 65/73 (89) 0.373 (0.173) 65/73 (89) 0.275 (0.184)
BCG 4/8 (50) -*** 4/8 (50) -*** 8/8 (100) -***
Non-BCG 55/65 (84.6) 0.085 (0.154) 61/65 (93.8) 0.567 (0.194) 57/65 (87.7) 0.268 (0.186)
* Indeterminate IFN-g assays results were not included in the analysis.
** standard deviation
*** value is not possible to calculate because of T-SPOT.TB and QFN-G-IT results are one constant variable.
Figure 1 Number of responder T cells to specific antigens in
T-SPOT.TB (A) and IFN-g released after specific antigens (B)
stimulation determined by QFN-G-IT in HIV-infected patients
stratifying CD4 cell counts into two groups of < 200 and >200
cells/μl.
Figure 2 IFN-g released after PHA stimulation determined by
QFN-G-IT in HIV-infected patients stratifying CD4 cell counts
into two groups of < 200 and >200 cells/μl.
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diagnosing LTBI in HIV population severely immuno-
suppressed. However, probably our results did not pro-
vide definite data for supporting these comments.
We only detected two indeterminate results (2.7%) by
either IFN-g assays. This data is consistent with the
majority of studies which show low rates of indetermi-
nate results in HIV-infected patients without active TB
[22]. One of the indeterminate cases obtained in our
study corresponded with a low circulating CD4 cell
count patient (103 cells/μl). It has been described that
low CD4 cell counts are associated with IFN-g assays
indeterminate results for the diagnosis of LTBI and
active TB [23,25,30,31,33,36,37]. However, in our study,
19 of 20 patients with < 200 CD4 cells/μlo b t a i n e da
valid result. This data differ from other studies where
high percentages of commercial IFN-g tests or in-house
ELISPOT assays indeterminate results were found in
HIV-infected patients with low CD4 count cells in LTBI
screening studies [23,25]. Nevertheless, studies of HIV-
infected patients with active TB, generally report higher
proportion of indeterminate results [36-38].
Raby et al [37] reported that low CD4 cell counts were
associated with both indeterminate and negative QFN-
G-IT results. On the contrary, low CD8 cell counts
(median 369 cells/μl) were only associated with indeter-
minate results. They proposed that CD4+ and CD8+
cells could respond to PHA, unfortunately, the MCH
class II overlapping peptides used in QFN-G-IT are only
restricted to CD4+ cells. Consequently, those patients
with high/normal CD8 cell counts (median 999 cells/μl)
and low CD4+ cells produced a positive response to
PHA but a negative response to M. tuberculosis specific
antigens. In our study, only one of the two indetermi-
nate results corresponded with a patient with a CD4 cell
count < 200 cells/μl and a CD8 cell count < 600 cells/μl
(103 and 568 cells/μl, respectively).
Regarding the differences in the IFN-g assays results in
HIV-positive individuals with a CD4 cell count < 200
respect those with a CD4 cell count >200, in our study
all tests performed poorly in HIV-infected patients with
CD4 cell count < 200. The fact that T-SPOT.TB
obtained a positive result in one individual with a CD4
cell count < 200 (39 cells/μl), but none for QFN-G-IT,
it is not sufficient to drawn conclusions. Converse et al
[39], assessed the effect of HIV immunosuppression on
QFN-G, and found that when immunosuppression
increased, QFN-G sensitivity decreased, and only 30%
(10/23) of HIV-seropositive persons with < 200 CD4
cells were positive.
Some studies have evaluated IFN-g assays in HIV
patients with active TB, and the influence of CD4 cell
count. Aabye et al [36], reported that QFN-G-IT sensi-
tivity in HIV-positive patients with active TB increased
with high CD4 cell counts. Additionally, there are stu-
dies that have determined the diagnostic accuracy of
T-cell based assays assessing the ratio of quantitative
response of ESAT-6 and CFP-10 to CD4 T cell count,
and improving the diagnosis of active TB [40,41]. No
HIV-infected patient diagnosed of active TB was
included in our study.
Furthermore, we observed that numbers of ESAT-6
and CFP-10 specific T cells in T-SPOT.TB, and concen-
tration of IFN-g in QFN-G-IT remained constant
among patients with different levels of immunosuppres-
sion. Our results differ with those obtained in a recent
study conducted by Leidl et al [26], where the correla-
tion of the number of CD4 T cells with the IFN-g
released in QFN-G-IT was positive (Spearman’sr h o=
0.38; p = 0.0001), and constant with the number of
ESAT-6 and CFP-10 specific T cells in T-SPOT.TB
(Spearman’s rho = 0.03; p = 0.77 and Spearman’sr h o=
0.13; p = 0.21, respectively).
Regarding the BCG-vaccination status, our results evi-
dence that T-cell based assays are less influenced by BCG-
vaccination than TST. In addition, we have found negative
IFN-g assays results among 2 non BCG-vaccinated HIV-
infected individuals with a positive TST. A possible expla-
nation to these discordant results could be a consequence
of a previous NTM sensitization. In fact, in our experi-
ence, the utilization of IFN-g tests could reduce the false
diagnosis of LTBI in patients with a NTM sensitization
[35,42]. In our study it was impossible to test in vitro
NTM sensitins given that we didn’th a v em o r eP B M C s
Figure 3 Correlation of numbers of circulating CD4 T cells with
responder T cells to ESAT-6 (A) and CFP-10 (B) in T-SPOT.TB,
and IFN-g released in QFN-G-IT (C).
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the safety of not treating BCG and non BCG-vaccinated
patients with a positive TST and negative T-cell based
assays in this kind of population, especially in patients
with more severe immunosuppression.
The main drawback of our study needs to be reported.
Even though we have compared T-SPOT.TB, QFN-G-IT
and TST in the same population of HIV-infected indivi-
duals, the number of patients, especially those with CD4
cell counts < 200, is limited. Furthermore, we did not
detect any significant differences in the overall percen-
tages of positive results between the three tests. How-
ever, our results reported in this study are consistent to
add valuable data about the utility of the IFN-g tests in
the diagnosis of LTBI in HIV-infected patients, and the
influence of the number of CD4 in the results. More
studies comparing T-SPOT.TB and QFN-G-IT with
TST are required to determine the role of IFN-g assays
for the diagnosis of LTBI in HIV-positive patients.
Conclusions
In conclusion, IFN-g tests have the benefit over TST that
are less influenced by BCG-vaccination, consequently they
are more specific than TST. The use of IFN-g assays in
combination with TST could be a helpful method for diag-
nosing LTBI in HIV population. Our study suggests that
IFN-g assays are influenced with level of immunosuppres-
sion. Further studies are required for understanding the
meaning of the discrepancies between both IFN-g tests.
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